The Hadassah Medical Center’s Molecular Pathology and Diagnostic Tumors Department is the first in the Middle East – and just the third outside of the United States – to conduct the new tumor diagnostic test FoundationOne-CDx (F1CDx) within its own laboratories.

F1CDx detects and identifies genetic changes in cancerous tumors. Looking at 324 genes within a single sample of a patient’s tissue, the test identifies substitutions, insertions, mutations, and alterations.

As a result, the new test will guide decisions regarding immunotherapy protocols and expand options for targeted personalized therapies. Read more at the following link.